Trial Profile
A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection, in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Pelgifatamab corixetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 17 Apr 2023 Planned End Date changed from 24 Nov 2023 to 22 Nov 2024.
- 30 May 2022 Status changed from recruiting to active, no longer recruiting.
- 30 May 2022 Planned End Date changed from 19 Sep 2024 to 24 Nov 2023.